

Joaquin Burgos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1650806/publications.pdf>

Version: 2024-02-01

50
papers

1,276
citations

471061

17
h-index

395343

33
g-index

57
all docs

57
docs citations

57
times ranked

1986
citing authors

#	ARTICLE	IF	CITATIONS
1	Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathogens, 2019, 15, e1007991.	2.1	119
2	Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nature Communications, 2021, 12, 3010.	5.8	111
3	A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 ⁺ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. MBio, 2017, 8, .	1.8	105
4	Current and Potential Usefulness of Pneumococcal Urinary Antigen Detection in Hospitalized Patients With Community-Acquired Pneumonia to Guide Antimicrobial Therapy. Archives of Internal Medicine, 2011, 171, 166-72.	4.3	103
5	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29,900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV, 2021, 8, e531-e543.	2.1	77
6	The increasing incidence of empyema. Current Opinion in Pulmonary Medicine, 2013, 19, 350-356.	1.2	75
7	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV, 2021, 8, e701-e710.	2.1	69
8	The Spectrum of Pneumococcal Empyema in Adults in the Early 21st Century. Clinical Infectious Diseases, 2011, 53, 254-261.	2.9	60
9	Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. Aids, 2015, 29, 695-702.	1.0	40
10	Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. European Respiratory Journal, 2014, 43, 545-553.	3.1	39
11	Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis. Clinical Microbiology and Infection, 2017, 23, 653-658.	2.8	38
12	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. Nature Communications, 2019, 10, 3705.	5.8	38
13	Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clinical Microbiology and Infection, 2013, 19, 385-391.	2.8	37
14	Effects of Immunocompromise and Comorbidities on Pneumococcal Serotypes Causing Invasive Respiratory Infection in Adults: Implications for Vaccine Strategies. Clinical Infectious Diseases, 2013, 57, 1722-1730.	2.9	36
15	The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men. HIV Medicine, 2016, 17, 524-531.	1.0	33
16	The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. Aids, 2017, 31, 2227-2233.	1.0	27
17	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 2479-2486.	1.3	24
18	Ceftibiprole medocaril for the treatment of community-acquired pneumonia. Expert Opinion on Pharmacotherapy, 2018, 19, 1503-1509.	0.9	17

#	ARTICLE	IF	CITATIONS
19	Invasive Pneumococcal Disease in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 31-38.	0.9	17
20	Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. <i>Aids</i> , 2017, 31, 1245-1252.	1.0	15
21	Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. <i>Pharmacotherapy</i> , 2019, 39, 501-507.	1.2	15
22	Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1453-1458.	1.3	14
23	Impact of Low-Level Viraemia on Virological Failure in HIV-1-Infected Patients with Stable Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2016, 21, 345-352.	0.6	14
24	The problem of early mortality in pneumococcal pneumonia: a study of risk factors. <i>European Respiratory Journal</i> , 2015, 46, 561-564.	3.1	13
25	An overview of lefamulin for the treatment of community acquired bacterial pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 629-636.	0.9	11
26	Fetuin-A, interleukin-6, trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. <i>Clinical and Translational Medicine</i> , 2022, 12, e704.	1.7	11
27	Acute Leg Ischaemia in an HIV-Infected Patient Receiving Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2017, 22, 89-90.	0.6	10
28	Investigational drugs in phase I and phase II clinical trials for the treatment of hospital-acquired pneumonia. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 653-665.	1.9	10
29	Impact of influenza season and environmental factors on the clinical presentation and outcome of invasive pneumococcal disease. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 177-186.	1.3	9
30	<p>Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 529-538.	1.5	9
31	Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1246.	1.0	9
32	Usefulness of Sofia Pneumococcal FIA® test in comparison with BinaxNOW® Pneumococcal test in urine samples for the diagnosis of pneumococcal pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1289-1295.	1.3	8
33	Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 612-616.	0.9	8
34	Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?. <i>AIDS Reviews</i> , 2018, 20, 3-13.	0.5	7
35	Determination of neutrophil CD64 expression as a prognostic biomarker in patients with community-acquired pneumonia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1411-1416.	1.3	6
36	Risk Factors for Relapse in Acute Bacterial Prostatitis: the Impact of Antibiotic Regimens. <i>Microbiology Spectrum</i> , 2021, 9, e0053421.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV-Coinfected Patients with Hepatic Cirrhosis Compared to Those in HIV-Monoinfected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6782-6790.	1.4	4
38	Chemical pharmacotherapy for hospital-acquired pneumonia in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 423-434.	0.9	4
39	Incidencia de neoplasias en una cohorte española de pacientes con infección por el virus de la inmunodeficiencia humana. <i>Medicina Clínica</i> , 2020, 155, 288-294.	0.3	3
40	An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1005-1013.	0.9	3
41	Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study. <i>HIV Medicine</i> , 2021, 22, 682-689.	1.0	3
42	An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1521-1531.	0.9	3
43	Organizing pneumonia secondary to influenza infection: Two case reports and a literature review. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 123-126.	0.3	3
44	Pharmacotherapeutic interventions for the treatment of bacterial prostatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1091-1101.	0.9	3
45	A case report of long treatment with Itraconazole in a patient with chronic Chagas disease. <i>BMC Infectious Diseases</i> , 2019, 19, 956.	1.3	2
46	Voriconazole and tamsulosin: A clinically relevant drug-drug interaction. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 361-363.	0.2	2
47	The Spectrum of Invasive Pneumococcal Disease in Adults in the XXI Century. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 214-220.	0.3	1
48	Organizing pneumonia secondary to influenza infection: Two case reports and a literature review. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 123-126.	0.2	1
49	Exploratory study of an oral screening dysplasia program for HIV-infected men who have sex with men. <i>Aids</i> , 0, Publish Ahead of Print, .	1.0	1
50	Infectious encephalitis: utility of a rational approach to aetiological diagnosis in daily clinical practice. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 641-648.	1.3	0